Galectin-3 Antibody (202213) [Unconjugated]

Western blot shows lysates of 4T1 mouse breast cancer cell line, Balb/3T3 mouse embryonic fibroblast cell line and HT-2 mouse T cell line. PVDF membrane was probed with 0.25 µg/mL of Rat Anti-Mouse Galectin-3 Monoclonal Antibody (Catalog # MAB1197) followed by HRP-conjugated Anti-Rat IgG Secondary Antibody (Catalog # HAF005). A specific band was detected for Galectin-3 at approximately 28 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Western blot shows lysates of MCF-7 human breast cancer cell line, U-118-MG human glioblastoma/astrocytoma cell line, C6 rat glioma cell line, and NR8383 rat alveolar macrophage cell line. PVDF membrane was probed with 0.5 µg/mL of Rat Anti-Mouse Galectin-3 Monoclonal Antibody (Catalog # MAB1197) followed by HRP-conjugated Anti-Rat IgG Secondary Antibody (Catalog # HAF005). A specific band was detected for Galectin-3 at approximately 28 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Simple Western lane view shows lysates of HT‑2 mouse T cell line and Balb/3T3 mouse embryonic fibroblast cell line, loaded at 0.2 mg/mL. A specific band was detected for Galectin‑3 at approximately 43 kDa (as indicated) using 10 µg/mL of Rat Anti-Mouse Galectin‑3 Monoclonal Antibody (Catalog # MAB1197) followed by 1:50 dilution of HRP-conjugated Anti-Rat IgG Secondary Antibody (Catalog # HAF005). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

A beta oligomerization and Gal-3 expression are age-dependently increased in APP/PS1 mice. a Wild-type (3 months old) and APP/PS1 mice of different ages (3, 5, 8, and 11 months) were sacrificed and dissected hippocampal tissues were subjected to Western blot analysis for endogenous A beta oligomers. b Quantified results for HMW and LMW A beta oligomerization [n = 4 per group; F(4,15) = 39.3, P 0.05]. e Immunohistochemical analysis showing the distributions of Gal-3 and ProteoStat staining in normal subjects and AD patients (n = 3 per group). Scale bar, 25 μm. DAPI was used to stain nuclei. Data are expressed as mean ± SEM. **P < 0.01, #P < 0.001 Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/31127200), licensed under a CC-BY license. Not internally tested by R&D Systems.

Endogenous Gal-3 expression is decreased but memory performance is improved in APP/PS1;Gal-3+/− mice. a Endogenous expression levels of Gal-3 and NEP were examined by Western blot analysis in 3-month-old WT;WT, APP/PS1;WT, WT;Gal-3−/− and APP/PS1;Gal-3+/− mice. b Quantified results for Gal-3 and NEP expression [n = 4 per group; for Gal-3, F(3,12) = 53.47, P < 0.001; q = 10.43, P < 0.001 for the WT;WT group versus the APP/PS1;WT group; q = 6.46, P < 0.001 for the APP/PS1;WT group versus the APP/PS1;Gal-3+/− group and q = 3.98, P < 0.05 for the WT;WT group versus the APP/PS1;Gal-3+/− group; for NEP, F(3,12) = 27.76, P < 0.001; q = 12.04, P < 0.001 for the WT;WT group versus the APP/PS1;WT group; q = 9.72, P < 0.001 for the WT;WT group versus the WT;Gal-3−/− group and q = 6.29, P < 0.01 for the WT;WT group versus the APP/PS1;Gal-3+/− group]. c Acquisition performance obtained by assessing the water maze learning of 8-month-old mice of the four genotypes [n = 7 per group; F(3,24) = 28.72, P < 0.001; q = 9.33, P < 0.001 for the APP/PS1;WT group versus the WT;WT group and q = 3.59, P < 0.05 for the APP/PS1;Gal-3+/− group versus the APP/PS1;WT group]. d Retention performance of the same mice described in (c) [n = 7 per group; F(3,24) = 4.76, P < 0.01; q = 3.94, P < 0.05 for the APP/PS1;WT group versus the WT;WT group; q = 3.25, P < 0.05 for the APP/PS1;Gal-3+/− group versus the APP/PS1;WT group for the target quadrant]. Representative swim patterns from each group are also shown (upper panel). Data are expressed as mean ± SEM. *P < 0.05, **P < 0.01, #P < 0.001 Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/31127200), licensed under a CC-BY license. Not internally tested by R&D Systems.

Galectin-3 associates with A beta and interacts with A beta . a Immunohistochemical analysis showing the distributions of endogenous Gal-3 and A beta in hippocampal samples of WT (left panel) and APP/PS1 (right panel) mice at 11 months of age. Scale bar, 200 μm. b Co-IP experiment showing preferential association of Gal-3 with endogenous A beta monomers in 8-month-old APP/PS1 mice. Experiments were performed in duplicate. c Different amounts of recombinant human Gal-3 protein (0.25, 0.5, 1, and 2 μg) were added to a solution containing A beta 42 peptide (15 μg), the mixture was subjected to a thioflavin-T assay, and fluorescence was measured hourly at different time points. The fluorescence plateaued at the 7-h time point. Experiments were performed in triplicate. The abbreviation “rh” indicates “recombinant human”. Data are expressed as mean ± SEM Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/31127200), licensed under a CC-BY license. Not internally tested by R&D Systems.

Tumor derived galectin-3 is a ligand for TREM2. (C) Immunohistochemical staining of galectin-3 in adjacent normal lung & intratumor areas of lung tissues (n = 5). Scale bars, 20 μm. Image collected & cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/39135069), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu, Mu, Rt
• Applications: WB, Simple Western, ELISA(Cap)
• Clone: 202213
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated
• Concentration: LYOPH

Galectin-3 Antibody (202213) [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant mouse Galectin‑3
  Ala2-Ile264
  Accession # P16110
• Specificity: Detects human, mouse, and rat Galectin-3 in Western blots. Detects human and mouse Galectin-3 in direct ELISAs. In direct ELISAs, no cross-reactivity with rhGalectin-2, -4, -8 or recombinant mouse Galectin-1, -4, or -7 is observed.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Gene: LGALS3
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Simple Western 10 ug/mL
  • Western Blot 0.25-0.5 ug/mL
• Application Notes: ELISA Capture: Mouse Galectin-3 Antibody (Catalog # MAB1197)
  ELISA Detection: Mouse Galectin-3 Biotinylated Antibody (Catalog # BAF1197)
  Standard: Recombinant Mouse Galectin-3 (Catalog # 1197-GA)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Galectin-3 Antibody (202213) [Unconjugated]

• AGE-R3
• Carbohydrate-binding protein 35
• CBP 35,35 kDa lectin
• CBP35
• GAL3
• Gal-3
• galactin-3
• Galactose-specific lectin 3
• Galactoside-binding protein
• GALBPCBP35
• Galectin3
• Galectin-3
• GALIG
• IgE-binding protein
• L29
• L31
• L-31
• Laminin-binding protein
• Lectin L-29
• lectin, galactoside-binding, soluble, 3
• LGALS2
• LGALS3
• Mac-2 antigen
• Mac-2
• MAC2GAL3

Background

The galectins constitute a large family of carbohydrate-binding proteins with specificity for N-acetyl-lactosamine-containing glycoproteins. At least 14 mammalian galectins, which share structural similarities in their carbohydrate recognition domains (CRD), have been identified. The galectins have been classified into the prototype galectins (-1, -2, -5, -7, -10, -11, -13, -14), which contain one CRD and exist either as a monomer or a noncovalent homodimer; the chimera galectins (Galectin-3) containing one CRD linked to a nonlectin domain; and the tandem-repeat galectins (-4, -6, -8, -9, -12) consisting of two CRDs joined by a linker peptide. Galectins lack a classical signal peptide and can be localized to the cytosolic compartments where they have intracellular functions. However, via one or more as yet unidentified non-classical secretory pathways, galectins can also be secreted to function extracellularly. Individual members of the galectin family have different tissue distribution profiles and exhibit subtle differences in their carbohydrate-binding specificities. Each family member may preferentially bind to a unique subset of cell-surface glycoproteins (1-4). Galectin-3, also known as Mac-2, L29, CBP35, and epsilon BP, is a chimera galectin that has a tendency to dimerize. Besides the soluble protein, alternatively spliced forms of chicken Galectin-3 containing a transmembrane-spanning domain and a leucine zipper motif have been reported. Galectin-3 is expressed in tumor cells, macrophages, activated T cells, osteoclasts, epithelial cells, and fibroblasts. It binds various matrix glycoproteins including laminin, fibronectin, LAMPS, 90K/Mac-2BP, MP20, and CEA. Galectin-3 promotes cell growth and proliferation for many cell types. Galectin-3 acts intracellularly to prevent apoptosis. Depending on the cell types, Galectin-3 exhibits pro- or anti-adhesive properties. Galectin-3 has proinflammatory activities in vitro and in vivo. It induces pro-inflammatory and inhibits Th2 type cytokine production. Galectin-3 chemoattracts monocytes and macrophages. It activates and degranulates basophils and mast cells. Elevated circulating levels of Galectin-3 has been show to correlate with the malignant potential of several types of cancer, suggesting that Galectin-3 is also involved in tumor growth and metastasis. Human and mouse Galectin-3 shares approximately 80% amino acid sequence similarity (1-5).

1. Rabinovich, A. et al. (2002) Trends in Immunol. 23:313.
2. Rabinovich, A. et al. (2002) J. Leukocyte Biology 71:741.
3. Hughes, R.C. (2001) Biochimie 83:667.
4. R&D Systems Cytokine Bulletin; Summer 2002.
5. Gorski, J.P. et al. (2002) J. Biol. Chem. 277:18840.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Galectin-3 Antibody (MAB1197)(7)

Publications using MAB1197

• Hao, WR;Chen, CC;Huang, GC;Lin, JH;Chen, HY;Liu, JC;Cheng, TH;Chen, JJ; Therapeutic Modulation of Mitophagy by Cafestol in Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis Nutrients 2025-11-25 [PMID: 41373971] (Western Blot, Mouse)
• Binder, NK;de Alwis, N;Beard, S;Fato, BR;Garg, A;Baird, L;Young, MJ;Hannan, NJ; Postpartum administration of eplerenone to mitigate vascular dysfunction in mice following a preeclampsia-like pregnancy Scientific reports 2025-05-27 [PMID: 40425613] (Immunohistochemistry, Mouse)
• CC Tao, KM Cheng, YL Ma, WL Hsu, YC Chen, JL Fuh, WJ Lee, CC Chao, EHY Lee Galectin-3 promotes A&amp;beta oligomerization and A&amp;beta toxicity in a mouse model of Alzheimer&#039;s disease Cell Death Differ., 2019-05-24;27(1):192-209. 2019-05-24 [PMID: 31127200] (Western Blot, Rat)
• T Clemente, NJ Vieira, JP Cerliani, C Adrain, A Luthi, MR Dominguez, M Yon, FC Barrence, TB Riul, RD Cummings, TM Zorn, S Amigorena, M Dias-Baruf, MM Rodrigues, SJ Martin, GA Rabinovich, GP Amarante-M Proteomic and functional analysis identifies galectin-1 as a novel regulatory component of the cytotoxic granule machinery Cell Death Dis, 2017-12-07;8(12):e3176. 2017-12-07 [PMID: 29215607] (Western Blot, Human)
• Yan-Chu Chen, Yun-Li Ma, Cheng-Hsiung Lin, Sin-Jhong Cheng, Wei-Lun Hsu, Eminy H.-Y. Lee Galectin-3 Negatively Regulates Hippocampus-Dependent Memory Formation through Inhibition of Integrin Signaling and Galectin-3 Phosphorylation Frontiers in Molecular Neuroscience 7/11/2017 [PMID: 28744198]
• Fermino M, Dias F, Lopes C, Souza M, Cruz A, Liu F, Chammas R, Roque-Barreira M, Rabinovich G, Bernardes E Galectin-3 negatively regulates the frequency and function of CD4(+) CD25(+) Foxp3(+) regulatory T cells and influences the course of Leishmania major infection. Eur J Immunol, 2013-05-17;43(7):1806-17. 2013-05-17 [PMID: 23592449] (IHC-Fr, Mouse)
• The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int, 2012-05-23;82(7):759-70. 2012-05-23 [PMID: 22622498] (Neutralization, Mouse)

Bioinformatics

• Gene Symbol: LGALS3
• Uniprot:
  • P16110()